Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 2021-11, Vol.35 (14), p.2399-2401
Hauptverfasser: Ruddy, Jake A., Boyarsky, Brian J., Bailey, Justin R., Karaba, Andrew H., Garonzik-Wang, Jacqueline M., Segev, Dorry L., Durand, Christine M., Werbel, William A.
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Viral
Antibody Formation
COVID-19
HIV Infections
Humans
RNA, Messenger
SARS-CoV-2
Vaccination
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
ISSN:0269-9370
1473-5571
1473-5571
DOI:10.1097/QAD.0000000000003017